These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12801612)

  • 1. Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.
    Lahoz C; Peña R; Mostaza JM; Jiménez J; Subirats E; Pintó X; Taboada M; López-Pastor A;
    Atherosclerosis; 2003 Jun; 168(2):289-95. PubMed ID: 12801612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X;
    Atherosclerosis; 2005 Sep; 182(1):129-34. PubMed ID: 16115483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
    Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated hypercholesterolemic response to a high-cholesterol diet in subjects heterozygous for the apolipoprotein A-IV-2 allele.
    McCombs RJ; Marcadis DE; Ellis J; Weinberg RB
    N Engl J Med; 1994 Sep; 331(11):706-10. PubMed ID: 8058077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
    Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins improve visual field alterations related to hypercholesterolemia.
    Alcalá A; Jansen S; Téllez T; Gómez-Huelgas R; Pérez O; Egido J; Farkouh ME
    Atherosclerosis; 2010 Apr; 209(2):510-4. PubMed ID: 19892351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia.
    Carmena-Ramon RF; Ordovas JM; Ascaso JF; Real J; Priego MA; Carmena R
    Atherosclerosis; 1998 Jul; 139(1):107-13. PubMed ID: 9699897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study.
    Talmud PJ; Ye S; Humphries SE
    Genet Epidemiol; 1994; 11(3):265-80. PubMed ID: 8088507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
    Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
    Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia].
    Schwartzkopff W; Bimmermann A; Schleicher J
    Arzneimittelforschung; 1990 Dec; 40(12):1322-7. PubMed ID: 2128866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol.
    Malin R; Laaksonen R; Knuuti J; Janatuinen T; Vesalainen R; Nuutila P; Lehtimäki T
    Pharmacogenetics; 2001 Oct; 11(7):625-33. PubMed ID: 11668222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation.
    Mata P; Lopez-Miranda J; Pocovi M; Alonso R; Lahoz C; Marin C; Garces C; Cenarro A; Perez-Jimenez F; de Oya M; Ordovas JM
    Atherosclerosis; 1998 Apr; 137(2):367-76. PubMed ID: 9622280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
    Nishimura R; Sone H; Nakagami T; Tajima N
    Diabetes Res Clin Pract; 2013 May; 100(2):e31-3. PubMed ID: 23522341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.